iShares Global Tech ETF vs Medtronic PLC — how do they compare? iShares Global Tech ETF trades at $137.18, while Medtronic PLC trades at $82.29 (market cap $106.61B). The key difference: Medtronic PLC pays a 3.46% dividend while iShares Global Tech ETF pays none, and iShares Global Tech ETF is trading nearer its 52-week high, Medtronic PLC nearer its low. Which is the better fit depends on your goals.
| IXN | MDT | |
|---|---|---|
Sector | Sector/Thematic | Health |
52-Week High | $149.74 | $105.35 |
52-Week Low | $94.04 | $73.75 |
Market Cap | — | $106.61B |
Enterprise Value | — | $125.36B |
Dividend Yield | — | 3.46% |
Signals from Pluang's Aura AI — not financial advice
IXN trades at $132.95 with minimal daily movement (+0.25%). Technical indicators show a neutral to bearish bias with mixed signals from moving averages and oscillators. The stock faces resistance near $139-$141 while finding support around $133-$136. Recent analysis highlights strong technology sector exposure but cautions about elevated valuations and concentration risks in the portfolio.
The outlook remains cautious as current price levels reflect significant optimism about AI-driven growth. Investment opportunity lies in continued technology sector leadership, while risks include valuation concerns and sector concentration. Analyst sentiment leans neutral with expectations for clearer earnings growth catalysts before more bullish positioning.
Medtronic (MDT) trades at $83.54, up 0.41% today, with a bullish technical signal from moving averages. The company reported strong revenue growth to $33.54B in 2025 and has beaten EPS estimates for three consecutive quarters. Recent acquisitions, including SPR and Scientia Vascular, expand its pain therapy and neurovascular portfolios. Valuation ratios show a P/E of 22.31 and P/S of 2.95, with a consensus price target of $97.50 implying significant upside.
The outlook is positive, supported by robust fundamentals, analyst optimism, and strategic expansions. Key risks include rising debt levels and competitive pressures in medical technology. With no sell ratings from analysts and a dividend yield near a decade high, MDT presents a compelling long-term opportunity for growth and income investors, though macroeconomic and execution risks warrant monitoring.
Trailing returns across standard periods
Latest headlines on both assets
IXN provides exposure to global electronics, software, and hardware companies. It tracks the S&P Global 1200 Information Technology Index, covering tech leaders across both developed and emerging markets.
Read more on IXN →One of the largest medical device companies, Medtronic develops and manufactures therapeutic medical devices for chronic diseases. Its portfolio includes pacemakers, defibrillators, heart valves, stents, insulin pumps, spinal fixation devices, neurovascular products, advanced energy, and surgical tools. The company markets its products to healthcare institutions and physicians in the United States and overseas. Foreign sales account for almost 50% of the company's total sales.
Read more on MDT →